<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="55">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on August 12, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04397757</url>
  </required_header>
  <id_info>
    <org_study_id>843003 (PennCCP-02)</org_study_id>
    <nct_id>NCT04397757</nct_id>
  </id_info>
  <brief_title>COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2.</brief_title>
  <official_title>An Open-Label, Controlled, Phase 1, Safety and Exploratory Efficacy Study of Convalescent Plasma for Severely Ill, Hospitalized Participants With COVID-19 Pneumonia Caused by SARS-CoV-2.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if this plasma can be safely used in humans with COVID-19&#xD;
      and to see if it improves patients' health as compared to not using it in patients with&#xD;
      pneumonia caused by SARS-CoV-2.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This open-label, randomized, controlled, phase 1 trial will assess the safety and efficacy of&#xD;
      convalescent plasma in severely ill, hospitalized participants with pneumonia due to&#xD;
      COVID-19. This study will enroll adults 18 years old and older, including pregnant women.&#xD;
&#xD;
      A total of 80 eligible participants will be randomized to receive either 2 units of&#xD;
      convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19 and&#xD;
      standard of care (treatment arm) or standard of care alone (control arm). Participants in the&#xD;
      treatment arm will receive 2 units of convalescent plasma on Study Day 1 in addition to&#xD;
      standard of care.&#xD;
&#xD;
      Participants will be assessed on study Day 1 (pre-dose), 30 minutes after each unit of&#xD;
      plasma, on all Study Days while hospitalized, and Study Days 15, 22, 29, and 60. All&#xD;
      participants will undergo a series of safety and efficacy, assessments. Blood samples will be&#xD;
      collected on Days 1 (prior to plasma administration), 3, 8, 15, 29, and 60. Oropharyngeal or&#xD;
      endotracheal samples will be collected on Days 1 (prior to plasma administration), 3, 5, 8,&#xD;
      11, and 15.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 13, 2020</start_date>
  <completion_date type="Actual">March 8, 2021</completion_date>
  <primary_completion_date type="Actual">February 6, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be randomized 1:1 to receive either convalescent plasma on Study Day 1 in addition to standard care or standard care alone.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participants With Serious Adverse Events.</measure>
    <time_frame>Up to Study Day 29</time_frame>
    <description>Number of participants with at least one serious adverse events (SAEs) up to Study Day 29.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Severity Score</measure>
    <time_frame>Up to Study Day 29</time_frame>
    <description>Clinical Severity Score (CSC) measured by both survival time, time to recovery (defined by reaching levels 1-3 of the WHO modified 8-Point Ordinal Severity scale), and disease course while hospitalized and is calculated based on a procedure proposed by Shaw and Fay 2016 (https://doi.org/10.1002/sim.6950). CSC ranges from 1 to 57. Higher CSC is worse outcome.&#xD;
Clinical status assessment (WHO modified 8-Point Ordinal Severity scale) includes:&#xD;
Not hospitalized, no limitations on activities.&#xD;
Not hospitalized, limitation on activities and/or requiring home oxygen;&#xD;
Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care;&#xD;
Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise);&#xD;
Hospitalized, requiring supplemental oxygen;&#xD;
Hospitalized, on non-invasive ventilation or high flow oxygen devices;&#xD;
Hospitalized, on invasive mechanical ventilation or ECMO;&#xD;
Death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Status Assessment, Time to Recovery</measure>
    <time_frame>Up to Study Day 29</time_frame>
    <description>Time to recovery, defined by time needed to reach levels 1-3 using the WHO modified 8-Point Ordinal Severity scale assessed daily while hospitalized and on Day 15, 22, and 29:&#xD;
Not hospitalized, no limitations on activities.&#xD;
Not hospitalized, limitation on activities and/or requiring home oxygen;&#xD;
Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care;&#xD;
Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise);&#xD;
Hospitalized, requiring supplemental oxygen;&#xD;
Hospitalized, on non-invasive ventilation or high flow oxygen devices;&#xD;
Hospitalized, on invasive mechanical ventilation or ECMO;&#xD;
Death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>National Early Warning Score (NEWS) Clinical Status Assessment</measure>
    <time_frame>Up to Study Day 29</time_frame>
    <description>Time to discharge or to a National Early Warning Score (NEWS) of â‰¤ 2 and maintained for 24 hours, whichever occurs first. NEWS assessed daily while hospitalized until discharge or death and on Days 15 and 29.&#xD;
Higher NEWS is worse, range from 0 to 20.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygenation</measure>
    <time_frame>Daily while hospitalized and up to Study Day 29</time_frame>
    <description>Days of supplemental oxygen while in hospital. defined as days with WHO8 ordinal score of 5, 6, or 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of New Oxygenation Use up to Day 29</measure>
    <time_frame>From enrollment to Day 29.</time_frame>
    <description>Incidence of new oxygenation use up to Day 29.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of New Oxygen Use up to Day 29</measure>
    <time_frame>From enrollment to Day 29.</time_frame>
    <description>Duration (days) of new oxygen use up to Day 29.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-invasive Ventilation/High Flow Oxygen Days up to Day 29</measure>
    <time_frame>Daily while in hospital to Study Day 29.</time_frame>
    <description>Days of non-invasive ventilation/high flow oxygen up to Day 29 Defined by having a WHO8 ordinal scale of 6 = Hospitalized, on non-invasive ventilation or high flow oxygen devices</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With at Least One Day on Non-invasive Ventilation/High Flow Oxygen up to Day 29</measure>
    <time_frame>Daily while in hospital until Study Day 29</time_frame>
    <description>number of participants with at least one day on non-invasive ventilation/high flow oxygen Defined by having a WHO8 ordinal scale of 6 = Hospitalized, on non-invasive ventilation or high flow oxygen devices</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Non-invasive Ventilation/High Flow Oxygen up to Day 29</measure>
    <time_frame>Daily while in hospital to Study Day 29.</time_frame>
    <description>Days of non-invasive ventilation/high flow oxygen up to Day 29</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator/ECMO Days to Day 29</measure>
    <time_frame>Daily while in hospital to Study Day 29</time_frame>
    <description>Days of mechanical ventilation or ECMO use (having a WHO8 ordinal score of 7 = Hospitalized, on invasive mechanical ventilation or ECMO) during the study in hospital until study day 29.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New Mechanical Ventilation or ECMO Use</measure>
    <time_frame>From enrollment to Day 29.</time_frame>
    <description>number of subjects with new mechanical ventilation or ECMO use up to Day 29 since all subjects were not on mechanical ventilation or ECMO at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of New Mechanical Ventilation or ECMO</measure>
    <time_frame>Daily while in hospital to Study Day 29</time_frame>
    <description>Days of new mechanical ventilation or ECMO use up to Day 29.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Hospitalization</measure>
    <time_frame>To Study Day 29</time_frame>
    <description>Duration (days) of first hospitalization. Time until death or discharge or Study Day 29</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>28 days from Study Day 1</time_frame>
    <description>28 day mortality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With SAEs Through Day 29</measure>
    <time_frame>Through Study Day 29</time_frame>
    <description>Number of subjects with SAEs through Day 29.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With at Least One Grade 3 and Grade 4 Clinical and/or Laboratory Adverse Events Through Day 29</measure>
    <time_frame>Through Study Day 29</time_frame>
    <description>Number of subjects with at least one Grade 3 or Grade 4 clinical and/or laboratory adverse events (AEs) through Day 29.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in WBC With Differential Through Day 29</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value &gt; baseline lab value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Hemoglobin Measurement Through Day 29</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value &gt; baseline lab value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Platelets Measurement Through Day 29</measure>
    <time_frame>Through Day 29.</time_frame>
    <description>Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value &gt; baseline lab value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Creatinine Measurement Through Day 29</measure>
    <time_frame>Through Day 29.</time_frame>
    <description>Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value &gt; baseline lab value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Glucose Measurement Through Day 29</measure>
    <time_frame>Through Day 29.</time_frame>
    <description>Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value &gt; baseline lab value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Total Bilirubin Measurement Through Day 29</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value &gt; baseline lab value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in ALT Measurement Through Day 29</measure>
    <time_frame>Through Day 29</time_frame>
    <description>Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value &gt; baseline lab value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in AST Measurement Through Day 29</measure>
    <time_frame>Through Day 29.</time_frame>
    <description>Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value &gt; baseline lab value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in PT Measurement Laboratory Through Day 29</measure>
    <time_frame>Through Day 29.</time_frame>
    <description>Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value &gt; baseline lab value.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>COVID-19 Convalescent plasma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>COVID-19 Convalescent plasma on Study Day 1 in addition to standard care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard care alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>COVID-19 Convalescent Plasma</intervention_name>
    <description>2 units of COVID-19 convalescent plasma compatible with their blood type</description>
    <arm_group_label>COVID-19 Convalescent plasma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult â‰¥18 years of age&#xD;
&#xD;
          2. Laboratory-confirmed SARS-CoV-2 infection as determined by PCR or other authorized or&#xD;
             approved assay in any specimen collected within 72 hours prior to enrollment.&#xD;
&#xD;
             Note - An exception must be requested to the Sponsor if â‰¥72 hours since positive test.&#xD;
&#xD;
          3. Hospitalized in participating facility.&#xD;
&#xD;
          4. Documentation of pneumonia with radiographic evidence of infiltrates by imaging (e.g.,&#xD;
             chest x-ray or CT scan).&#xD;
&#xD;
          5. Abnormal respiratory status that is judged worse than baseline by the investigator and&#xD;
             as documented at any point within 24 hours prior to randomization, consistent with&#xD;
             ordinal scale levels 5, 6 or 7, specifically defined as:&#xD;
&#xD;
               -  Room air saturation of oxygen (SaO2) &lt; 93%, OR&#xD;
&#xD;
               -  Requiring supplemental oxygen, OR&#xD;
&#xD;
               -  Tachypnea with respiratory rate â‰¥30&#xD;
&#xD;
          6. Patient or proxy is willing and able to provide written informed consent and comply&#xD;
             with all protocol requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Contraindication to transfusion (e.g., severe volume overload, history of severe&#xD;
             allergic reaction to blood products), as judged by the investigator.&#xD;
&#xD;
          2. Clinical suspicion that the etiology of acute illness (acute decompensation) is&#xD;
             primarily due to a condition other than COVID-19&#xD;
&#xD;
          3. Receipt of other investigational therapy as a part of another clinical trial. Note:&#xD;
             investigational therapies used as part of clinical care, (eg, remdesivir,&#xD;
             hydroxychloroquine) are permissible.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katharine J. Bar</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2022</verification_date>
  <study_first_submitted>May 19, 2020</study_first_submitted>
  <study_first_submitted_qc>May 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2020</study_first_posted>
  <results_first_submitted>January 11, 2022</results_first_submitted>
  <results_first_submitted_qc>March 31, 2022</results_first_submitted_qc>
  <results_first_posted type="Actual">April 19, 2022</results_first_posted>
  <last_update_submitted>March 31, 2022</last_update_submitted>
  <last_update_submitted_qc>March 31, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Convalescent plasma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 28, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/57/NCT04397757/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>COVID-19 Convalescent Plasma</title>
          <description>On Day 1 subjects receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19 followed by standard of care</description>
        </group>
        <group group_id="P2">
          <title>Standard of Care</title>
          <description>Standard of care treatment administered only</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>One subject (Subject CCP2-043) in treatment plasma arm discontinued/withdrew from study immediately after enrollment before receipt of plasma and was excluded from analysis.</population>
      <group_list>
        <group group_id="B1">
          <title>COVID-19 Convalescent Plasma</title>
          <description>COVID-19 Convalescent plasma on Study Day 1 in addition to standard care&#xD;
COVID-19 Convalescent Plasma: 2 units of COVID-19 convalescent plasma compatible with their blood type</description>
        </group>
        <group group_id="B2">
          <title>Standard of Care</title>
          <description>Standard care alone</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="39"/>
            <count group_id="B3" value="79"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Participants With Serious Adverse Events.</title>
        <description>Number of participants with at least one serious adverse events (SAEs) up to Study Day 29.</description>
        <time_frame>Up to Study Day 29</time_frame>
        <group_list>
          <group group_id="O1">
            <title>COVID-19 Convalescent Plasma</title>
            <description>COVID-19 Convalescent plasma on Study Day 1 in addition to standard care&#xD;
COVID-19 Convalescent Plasma: 2 units of COVID-19 convalescent plasma compatible with their blood type</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Standard care alone</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Serious Adverse Events.</title>
          <description>Number of participants with at least one serious adverse events (SAEs) up to Study Day 29.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Severity Score</title>
        <description>Clinical Severity Score (CSC) measured by both survival time, time to recovery (defined by reaching levels 1-3 of the WHO modified 8-Point Ordinal Severity scale), and disease course while hospitalized and is calculated based on a procedure proposed by Shaw and Fay 2016 (https://doi.org/10.1002/sim.6950). CSC ranges from 1 to 57. Higher CSC is worse outcome.&#xD;
Clinical status assessment (WHO modified 8-Point Ordinal Severity scale) includes:&#xD;
Not hospitalized, no limitations on activities.&#xD;
Not hospitalized, limitation on activities and/or requiring home oxygen;&#xD;
Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care;&#xD;
Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise);&#xD;
Hospitalized, requiring supplemental oxygen;&#xD;
Hospitalized, on non-invasive ventilation or high flow oxygen devices;&#xD;
Hospitalized, on invasive mechanical ventilation or ECMO;&#xD;
Death</description>
        <time_frame>Up to Study Day 29</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>On Day 1 subjects receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19 followed by standard of care</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Standard of care treatment administered only</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Severity Score</title>
          <description>Clinical Severity Score (CSC) measured by both survival time, time to recovery (defined by reaching levels 1-3 of the WHO modified 8-Point Ordinal Severity scale), and disease course while hospitalized and is calculated based on a procedure proposed by Shaw and Fay 2016 (https://doi.org/10.1002/sim.6950). CSC ranges from 1 to 57. Higher CSC is worse outcome.&#xD;
Clinical status assessment (WHO modified 8-Point Ordinal Severity scale) includes:&#xD;
Not hospitalized, no limitations on activities.&#xD;
Not hospitalized, limitation on activities and/or requiring home oxygen;&#xD;
Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care;&#xD;
Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise);&#xD;
Hospitalized, requiring supplemental oxygen;&#xD;
Hospitalized, on non-invasive ventilation or high flow oxygen devices;&#xD;
Hospitalized, on invasive mechanical ventilation or ECMO;&#xD;
Death</description>
          <units>scored on a scale (CSC)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="2.75" upper_limit="12.5"/>
                    <measurement group_id="O2" value="10" lower_limit="5.5" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Status Assessment, Time to Recovery</title>
        <description>Time to recovery, defined by time needed to reach levels 1-3 using the WHO modified 8-Point Ordinal Severity scale assessed daily while hospitalized and on Day 15, 22, and 29:&#xD;
Not hospitalized, no limitations on activities.&#xD;
Not hospitalized, limitation on activities and/or requiring home oxygen;&#xD;
Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care;&#xD;
Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise);&#xD;
Hospitalized, requiring supplemental oxygen;&#xD;
Hospitalized, on non-invasive ventilation or high flow oxygen devices;&#xD;
Hospitalized, on invasive mechanical ventilation or ECMO;&#xD;
Death</description>
        <time_frame>Up to Study Day 29</time_frame>
        <population>Population analyzed are only those who recovered. Remaining subjects either died or were still in hospital with WHO8 score &gt; 3 by Study Day 29.</population>
        <group_list>
          <group group_id="O1">
            <title>COVID-19 Convalescent Plasma</title>
            <description>COVID-19 Convalescent plasma on Study Day 1 in addition to standard care&#xD;
COVID-19 Convalescent Plasma: 2 units of COVID-19 convalescent plasma compatible with their blood type</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>Standard care alone</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Status Assessment, Time to Recovery</title>
          <description>Time to recovery, defined by time needed to reach levels 1-3 using the WHO modified 8-Point Ordinal Severity scale assessed daily while hospitalized and on Day 15, 22, and 29:&#xD;
Not hospitalized, no limitations on activities.&#xD;
Not hospitalized, limitation on activities and/or requiring home oxygen;&#xD;
Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care;&#xD;
Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise);&#xD;
Hospitalized, requiring supplemental oxygen;&#xD;
Hospitalized, on non-invasive ventilation or high flow oxygen devices;&#xD;
Hospitalized, on invasive mechanical ventilation or ECMO;&#xD;
Death</description>
          <population>Population analyzed are only those who recovered. Remaining subjects either died or were still in hospital with WHO8 score &gt; 3 by Study Day 29.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="2.25" upper_limit="11.75"/>
                    <measurement group_id="O2" value="7" lower_limit="4.25" upper_limit="9.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>National Early Warning Score (NEWS) Clinical Status Assessment</title>
        <description>Time to discharge or to a National Early Warning Score (NEWS) of â‰¤ 2 and maintained for 24 hours, whichever occurs first. NEWS assessed daily while hospitalized until discharge or death and on Days 15 and 29.&#xD;
Higher NEWS is worse, range from 0 to 20.</description>
        <time_frame>Up to Study Day 29</time_frame>
        <population>subjects who never reach National Early Warning Score (NEWS) of â‰¤ 2 or discharged by Study Day 29 have outcome measure of Infinity</population>
        <group_list>
          <group group_id="O1">
            <title>COVID-19 Convalescent Plasma</title>
            <description>COVID-19 Convalescent plasma on Study Day 1 in addition to standard care&#xD;
COVID-19 Convalescent Plasma: 2 units of COVID-19 convalescent plasma compatible with their blood type</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>Standard care alone</description>
          </group>
        </group_list>
        <measure>
          <title>National Early Warning Score (NEWS) Clinical Status Assessment</title>
          <description>Time to discharge or to a National Early Warning Score (NEWS) of â‰¤ 2 and maintained for 24 hours, whichever occurs first. NEWS assessed daily while hospitalized until discharge or death and on Days 15 and 29.&#xD;
Higher NEWS is worse, range from 0 to 20.</description>
          <population>subjects who never reach National Early Warning Score (NEWS) of â‰¤ 2 or discharged by Study Day 29 have outcome measure of Infinity</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="2" upper_limit="6.25"/>
                    <measurement group_id="O2" value="4" lower_limit="2" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Oxygenation</title>
        <description>Days of supplemental oxygen while in hospital. defined as days with WHO8 ordinal score of 5, 6, or 7</description>
        <time_frame>Daily while hospitalized and up to Study Day 29</time_frame>
        <population>All subjects were evaluated. Subjects who never had a day with WHO8 ordinal score of 5, 6, or 7 have outcome measurement of 0 days.</population>
        <group_list>
          <group group_id="O1">
            <title>COVID-19 Convalescent Plasma</title>
            <description>On Day 1 subjects receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19 followed by standard of care</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Standard of care treatment administered only</description>
          </group>
        </group_list>
        <measure>
          <title>Oxygenation</title>
          <description>Days of supplemental oxygen while in hospital. defined as days with WHO8 ordinal score of 5, 6, or 7</description>
          <population>All subjects were evaluated. Subjects who never had a day with WHO8 ordinal score of 5, 6, or 7 have outcome measurement of 0 days.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="2" upper_limit="10.25"/>
                    <measurement group_id="O2" value="8" lower_limit="4" upper_limit="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of New Oxygenation Use up to Day 29</title>
        <description>Incidence of new oxygenation use up to Day 29.</description>
        <time_frame>From enrollment to Day 29.</time_frame>
        <population>this endpoint was not measured due to redundancy</population>
        <group_list>
          <group group_id="O1">
            <title>COVID-19 Convalescent Plasma</title>
            <description>On Day 1 subjects receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19 followed by standard of care</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Standard of care treatment administered only</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of New Oxygenation Use up to Day 29</title>
          <description>Incidence of new oxygenation use up to Day 29.</description>
          <population>this endpoint was not measured due to redundancy</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of New Oxygen Use up to Day 29</title>
        <description>Duration (days) of new oxygen use up to Day 29.</description>
        <time_frame>From enrollment to Day 29.</time_frame>
        <population>This was not measured due to redundancy of endpoints</population>
        <group_list>
          <group group_id="O1">
            <title>COVID-19 Convalescent Plasma</title>
            <description>On Day 1 subjects receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19 followed by standard of care</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Standard of care treatment administered only</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of New Oxygen Use up to Day 29</title>
          <description>Duration (days) of new oxygen use up to Day 29.</description>
          <population>This was not measured due to redundancy of endpoints</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-invasive Ventilation/High Flow Oxygen Days up to Day 29</title>
        <description>Days of non-invasive ventilation/high flow oxygen up to Day 29 Defined by having a WHO8 ordinal scale of 6 = Hospitalized, on non-invasive ventilation or high flow oxygen devices</description>
        <time_frame>Daily while in hospital to Study Day 29.</time_frame>
        <population>All subjects were evaluated. Subjects who never had a day with WHO8 ordinal score of 6 have outcome measurement of 0 days.</population>
        <group_list>
          <group group_id="O1">
            <title>COVID-19 Convalescent Plasma</title>
            <description>COVID-19 Convalescent plasma on Study Day 1 in addition to standard care&#xD;
COVID-19 Convalescent Plasma: 2 units of COVID-19 convalescent plasma compatible with their blood type</description>
          </group>
          <group group_id="O2">
            <title>Standard Care</title>
            <description>Standard care alone</description>
          </group>
        </group_list>
        <measure>
          <title>Non-invasive Ventilation/High Flow Oxygen Days up to Day 29</title>
          <description>Days of non-invasive ventilation/high flow oxygen up to Day 29 Defined by having a WHO8 ordinal scale of 6 = Hospitalized, on non-invasive ventilation or high flow oxygen devices</description>
          <population>All subjects were evaluated. Subjects who never had a day with WHO8 ordinal score of 6 have outcome measurement of 0 days.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0" upper_limit="5"/>
                    <measurement group_id="O2" value="3" lower_limit="0" upper_limit="5.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With at Least One Day on Non-invasive Ventilation/High Flow Oxygen up to Day 29</title>
        <description>number of participants with at least one day on non-invasive ventilation/high flow oxygen Defined by having a WHO8 ordinal scale of 6 = Hospitalized, on non-invasive ventilation or high flow oxygen devices</description>
        <time_frame>Daily while in hospital until Study Day 29</time_frame>
        <group_list>
          <group group_id="O1">
            <title>COVID-19 Convalescent Plasma</title>
            <description>On Day 1 subjects receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19 followed by standard of care</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Standard of care treatment administered only</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With at Least One Day on Non-invasive Ventilation/High Flow Oxygen up to Day 29</title>
          <description>number of participants with at least one day on non-invasive ventilation/high flow oxygen Defined by having a WHO8 ordinal scale of 6 = Hospitalized, on non-invasive ventilation or high flow oxygen devices</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Non-invasive Ventilation/High Flow Oxygen up to Day 29</title>
        <description>Days of non-invasive ventilation/high flow oxygen up to Day 29</description>
        <time_frame>Daily while in hospital to Study Day 29.</time_frame>
        <population>not measured due to redundancy with other endpoints (#8)</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>On Day 1 subjects receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19 followed by standard of care</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Standard of care treatment administered only</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Non-invasive Ventilation/High Flow Oxygen up to Day 29</title>
          <description>Days of non-invasive ventilation/high flow oxygen up to Day 29</description>
          <population>not measured due to redundancy with other endpoints (#8)</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ventilator/ECMO Days to Day 29</title>
        <description>Days of mechanical ventilation or ECMO use (having a WHO8 ordinal score of 7 = Hospitalized, on invasive mechanical ventilation or ECMO) during the study in hospital until study day 29.</description>
        <time_frame>Daily while in hospital to Study Day 29</time_frame>
        <population>All subjects were evaluated. Subjects who never had a day with WHO8 ordinal score of 7 have outcome measurement of 0 days.</population>
        <group_list>
          <group group_id="O1">
            <title>COVID-19 Convalescent Plasma</title>
            <description>On Day 1 subjects receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19 followed by standard of care</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Standard of care treatment administered only</description>
          </group>
        </group_list>
        <measure>
          <title>Ventilator/ECMO Days to Day 29</title>
          <description>Days of mechanical ventilation or ECMO use (having a WHO8 ordinal score of 7 = Hospitalized, on invasive mechanical ventilation or ECMO) during the study in hospital until study day 29.</description>
          <population>All subjects were evaluated. Subjects who never had a day with WHO8 ordinal score of 7 have outcome measurement of 0 days.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>New Mechanical Ventilation or ECMO Use</title>
        <description>number of subjects with new mechanical ventilation or ECMO use up to Day 29 since all subjects were not on mechanical ventilation or ECMO at baseline.</description>
        <time_frame>From enrollment to Day 29.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>COVID-19 Convalescent Plasma</title>
            <description>On Day 1 subjects receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19 followed by standard of care</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Standard of care treatment administered only</description>
          </group>
        </group_list>
        <measure>
          <title>New Mechanical Ventilation or ECMO Use</title>
          <description>number of subjects with new mechanical ventilation or ECMO use up to Day 29 since all subjects were not on mechanical ventilation or ECMO at baseline.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of New Mechanical Ventilation or ECMO</title>
        <description>Days of new mechanical ventilation or ECMO use up to Day 29.</description>
        <time_frame>Daily while in hospital to Study Day 29</time_frame>
        <population>only includes subjects with new mechanical ventilation or ECMO</population>
        <group_list>
          <group group_id="O1">
            <title>COVID-19 Convalescent Plasma</title>
            <description>On Day 1 subjects receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19 followed by standard of care</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Standard of care treatment administered only</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of New Mechanical Ventilation or ECMO</title>
          <description>Days of new mechanical ventilation or ECMO use up to Day 29.</description>
          <population>only includes subjects with new mechanical ventilation or ECMO</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="4" upper_limit="8"/>
                    <measurement group_id="O2" value="12.5" lower_limit="10" upper_limit="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Hospitalization</title>
        <description>Duration (days) of first hospitalization. Time until death or discharge or Study Day 29</description>
        <time_frame>To Study Day 29</time_frame>
        <group_list>
          <group group_id="O1">
            <title>COVID-19 Convalescent Plasma</title>
            <description>On Day 1 subjects receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19 followed by standard of care</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Standard of care treatment administered only</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Hospitalization</title>
          <description>Duration (days) of first hospitalization. Time until death or discharge or Study Day 29</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" lower_limit="2.75" upper_limit="12"/>
                    <measurement group_id="O2" value="9" lower_limit="5" upper_limit="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mortality</title>
        <description>28 day mortality.</description>
        <time_frame>28 days from Study Day 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>COVID-19 Convalescent Plasma</title>
            <description>On Day 1 subjects receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19 followed by standard of care</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Standard of care treatment administered only</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality</title>
          <description>28 day mortality.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With SAEs Through Day 29</title>
        <description>Number of subjects with SAEs through Day 29.</description>
        <time_frame>Through Study Day 29</time_frame>
        <population>this endpoint is redundant with the primary endpoint</population>
        <group_list>
          <group group_id="O1">
            <title>COVID-19 Convalescent Plasma</title>
            <description>On Day 1 subjects receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19 followed by standard of care</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Standard of care treatment administered only</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With SAEs Through Day 29</title>
          <description>Number of subjects with SAEs through Day 29.</description>
          <population>this endpoint is redundant with the primary endpoint</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With at Least One Grade 3 and Grade 4 Clinical and/or Laboratory Adverse Events Through Day 29</title>
        <description>Number of subjects with at least one Grade 3 or Grade 4 clinical and/or laboratory adverse events (AEs) through Day 29.</description>
        <time_frame>Through Study Day 29</time_frame>
        <group_list>
          <group group_id="O1">
            <title>COVID-19 Convalescent Plasma</title>
            <description>On Day 1 subjects receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19 followed by standard of care</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Standard of care treatment administered only</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With at Least One Grade 3 and Grade 4 Clinical and/or Laboratory Adverse Events Through Day 29</title>
          <description>Number of subjects with at least one Grade 3 or Grade 4 clinical and/or laboratory adverse events (AEs) through Day 29.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in WBC With Differential Through Day 29</title>
        <description>Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value &gt; baseline lab value.</description>
        <time_frame>Through Day 29</time_frame>
        <population>Defined changes as difference between last measured lab value and baseline (day 1) lab value. Day of last measured lab may differ among subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>COVID-19 Convalescent Plasma</title>
            <description>On Day 1 subjects receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19 followed by standard of care</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Standard of care treatment administered only</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in WBC With Differential Through Day 29</title>
          <description>Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value &gt; baseline lab value.</description>
          <population>Defined changes as difference between last measured lab value and baseline (day 1) lab value. Day of last measured lab may differ among subjects.</population>
          <units>THO/uL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.45" lower_limit="-1.30" upper_limit="3.30"/>
                    <measurement group_id="O2" value="2.50" lower_limit="0.25" upper_limit="3.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Hemoglobin Measurement Through Day 29</title>
        <description>Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value &gt; baseline lab value.</description>
        <time_frame>Through Day 29</time_frame>
        <population>Defined changes as difference between last measured lab value and baseline (day 1) lab value. Day of last measured lab may differ among subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>COVID-19 Convalescent Plasma</title>
            <description>On Day 1 subjects receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19 followed by standard of care</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Standard of care treatment administered only</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Hemoglobin Measurement Through Day 29</title>
          <description>Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value &gt; baseline lab value.</description>
          <population>Defined changes as difference between last measured lab value and baseline (day 1) lab value. Day of last measured lab may differ among subjects.</population>
          <units>g/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.35" lower_limit="-1.20" upper_limit="0.325"/>
                    <measurement group_id="O2" value="-0.30" lower_limit="-1.90" upper_limit="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Platelets Measurement Through Day 29</title>
        <description>Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value &gt; baseline lab value.</description>
        <time_frame>Through Day 29.</time_frame>
        <population>Defined changes as difference between last measured lab value and baseline (day 1) lab value. Day of last measured lab may differ among subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>COVID-19 Convalescent Plasma</title>
            <description>On Day 1 subjects receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19 followed by standard of care</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Standard of care treatment administered only</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Platelets Measurement Through Day 29</title>
          <description>Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value &gt; baseline lab value.</description>
          <population>Defined changes as difference between last measured lab value and baseline (day 1) lab value. Day of last measured lab may differ among subjects.</population>
          <units>10^3 platelets per uL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38" lower_limit="-5.50" upper_limit="129"/>
                    <measurement group_id="O2" value="59" lower_limit="4.50" upper_limit="94.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Creatinine Measurement Through Day 29</title>
        <description>Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value &gt; baseline lab value.</description>
        <time_frame>Through Day 29.</time_frame>
        <population>Defined changes as difference between last measured lab value and baseline (day 1) lab value. Day of last measured lab may differ among subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>COVID-19 Convalescent Plasma</title>
            <description>On Day 1 subjects receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19 followed by standard of care</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Standard of care treatment administered only</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Creatinine Measurement Through Day 29</title>
          <description>Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value &gt; baseline lab value.</description>
          <population>Defined changes as difference between last measured lab value and baseline (day 1) lab value. Day of last measured lab may differ among subjects.</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.035" lower_limit="-0.160" upper_limit="0.220"/>
                    <measurement group_id="O2" value="-0.050" lower_limit="-0.255" upper_limit="0.055"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Glucose Measurement Through Day 29</title>
        <description>Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value &gt; baseline lab value.</description>
        <time_frame>Through Day 29.</time_frame>
        <population>Defined changes as difference between last measured lab value and baseline (day 1) lab value. Day of last measured lab may differ among subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>COVID-19 Convalescent Plasma</title>
            <description>On Day 1 subjects receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19 followed by standard of care</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Standard of care treatment administered only</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Glucose Measurement Through Day 29</title>
          <description>Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value &gt; baseline lab value.</description>
          <population>Defined changes as difference between last measured lab value and baseline (day 1) lab value. Day of last measured lab may differ among subjects.</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.00" lower_limit="-34.75" upper_limit="13.75"/>
                    <measurement group_id="O2" value="-20.00" lower_limit="-48.50" upper_limit="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Total Bilirubin Measurement Through Day 29</title>
        <description>Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value &gt; baseline lab value.</description>
        <time_frame>Through Day 29</time_frame>
        <population>Defined changes as difference between last measured lab value and baseline (day 1) lab value. Day of last measured lab may differ among subjects.&#xD;
Standard of care arm has analyzed sample size of 38 because one subject did not have total bilirubin lab collected</population>
        <group_list>
          <group group_id="O1">
            <title>COVID-19 Convalescent Plasma</title>
            <description>On Day 1 subjects receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19 followed by standard of care</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Standard of care treatment administered only</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Total Bilirubin Measurement Through Day 29</title>
          <description>Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value &gt; baseline lab value.</description>
          <population>Defined changes as difference between last measured lab value and baseline (day 1) lab value. Day of last measured lab may differ among subjects.&#xD;
Standard of care arm has analyzed sample size of 38 because one subject did not have total bilirubin lab collected</population>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-0.10" upper_limit="0.10"/>
                    <measurement group_id="O2" value="0.00" lower_limit="0.00" upper_limit="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in ALT Measurement Through Day 29</title>
        <description>Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value &gt; baseline lab value.</description>
        <time_frame>Through Day 29</time_frame>
        <population>Defined changes as difference between last measured lab value and baseline (day 1) lab value. Day of last measured lab may differ among subjects.&#xD;
Standard of care arm has analyzed sample size of 38 because one subject did not have ALT lab collected</population>
        <group_list>
          <group group_id="O1">
            <title>COVID-19 Convalescent Plasma</title>
            <description>On Day 1 subjects receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19 followed by standard of care</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Standard of care treatment administered only</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in ALT Measurement Through Day 29</title>
          <description>Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value &gt; baseline lab value.</description>
          <population>Defined changes as difference between last measured lab value and baseline (day 1) lab value. Day of last measured lab may differ among subjects.&#xD;
Standard of care arm has analyzed sample size of 38 because one subject did not have ALT lab collected</population>
          <units>U/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-5.75" upper_limit="5.00"/>
                    <measurement group_id="O2" value="-1.00" lower_limit="-11.50" upper_limit="8.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in AST Measurement Through Day 29</title>
        <description>Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value &gt; baseline lab value.</description>
        <time_frame>Through Day 29.</time_frame>
        <population>Defined changes as difference between last measured lab value and baseline (day 1) lab value. Day of last measured lab may differ among subjects.&#xD;
Standard of care arm has analyzed sample size of 38 because one subject did not have AST lab collected</population>
        <group_list>
          <group group_id="O1">
            <title>COVID-19 Convalescent Plasma</title>
            <description>On Day 1 subjects receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19 followed by standard of care</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Standard of care treatment administered only</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in AST Measurement Through Day 29</title>
          <description>Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value &gt; baseline lab value.</description>
          <population>Defined changes as difference between last measured lab value and baseline (day 1) lab value. Day of last measured lab may differ among subjects.&#xD;
Standard of care arm has analyzed sample size of 38 because one subject did not have AST lab collected</population>
          <units>U/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.00" lower_limit="-16.00" upper_limit="0.00"/>
                    <measurement group_id="O2" value="-6.00" lower_limit="-16.00" upper_limit="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in PT Measurement Laboratory Through Day 29</title>
        <description>Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value &gt; baseline lab value.</description>
        <time_frame>Through Day 29.</time_frame>
        <population>Defined changes as difference between last measured lab value and baseline (day 1) lab value. Day of last measured lab may differ among subjects.&#xD;
Plasma arm analyzed sample size is 38 because 2 subjects did not have PT test collected.&#xD;
Standard of care arm analyzed sample size is 37 because 2 subjects did not have PT test collected.</population>
        <group_list>
          <group group_id="O1">
            <title>COVID-19 Convalescent Plasma</title>
            <description>On Day 1 subjects receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19 followed by standard of care</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care</title>
            <description>Standard of care treatment administered only</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in PT Measurement Laboratory Through Day 29</title>
          <description>Collected labs on Days 1 (baseline), 3, 5, 8, and 11 (while hospitalized), Days 15 and 29 (if attends in person visit or still hospitalized). Changes measured as difference between last measured lab value and baseline lab value. A negative value indicates last lab value &gt; baseline lab value.</description>
          <population>Defined changes as difference between last measured lab value and baseline (day 1) lab value. Day of last measured lab may differ among subjects.&#xD;
Plasma arm analyzed sample size is 38 because 2 subjects did not have PT test collected.&#xD;
Standard of care arm analyzed sample size is 37 because 2 subjects did not have PT test collected.</population>
          <units>seconds</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-1.175" upper_limit="0.550"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-0.8" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to Study Day 60</time_frame>
      <desc>41 subjects were enrolled in the treatment arm; 1 subject withdrew consent prior to initiate any research activities; Only 40 were placed at risk.</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment</title>
          <description>On Day 1 subjects receive 2 units of convalescent plasma collected from ABO-compatible donors who have recovered from COVID-19 followed by standard of care</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>Standard of care treatment administered only</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>DAIDS 2.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia (by ECG or physical examination)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Glucose low</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Creatinine High</sub_title>
                <description>Creatinine greater than 2x baseline</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered Mental Status</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Neurosensory alteration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea or Respiratory Distress</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="40"/>
                <counts group_id="E2" events="18" subjects_affected="13" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Acute CNS Ischemia</sub_title>
                <description>Transient ischemic attack; cerebral vascular accident</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>DAIDS 2.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin, Low (g/dL; mmol/L) &gt;= 13 years of age (female only)</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E2" events="14" subjects_affected="8" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Platelets, Decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hemoglobin, Low (g/dL; mmol/L) &gt;= 13 years of age (male only)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" events="10" subjects_affected="6" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Thrombosis or Embolism Report only one</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia (by ECG or physical examination)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal Bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever (non-axillary temperatures only)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pain (not associated with study agent injections and not specified elsewhere)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>AST, High</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Creatinine, High</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>ALT High</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Calcium, Low (mg/dL; mmol/L) &gt;= 7 days of age</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="40"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Albumin, Low</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Alkalosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Glucose (mg/dL; mmol/L) Fasting, High</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="40"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Altered Mental Status</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Acute CNS Ischemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea or Respiratory Distress</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="40"/>
                <counts group_id="E2" events="32" subjects_affected="14" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus (without skin lesions)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Blood Pressure Abnormalities Hypertension (with the lowest reading taken after repeat testing durin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Regulatory Lead</name_or_title>
      <organization>University of Pennsylvania</organization>
      <phone>512-662-4484</phone>
      <email>psom-ind-ide@pobox.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

